Reports Q3 revenue $3.08M vs. $3.1M last year. Mytesi prescription volume increased by approximately 0.9% in the third quarter of 2025 over the second quarter of 2025, and Mytesi prescription volume in the third quarter of 2025 decreased by 3.6% compared to the volume in the third quarter of 2024. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Animal Health Secures $10.8M Note Agreement
- Jaguar Health provides recap of presentation on crofelemer results
- Jaguar Health to present initial results from PoC study of crofelemer
- Jaguar Health completes FDA Type C meeting on crofelemer trial
- Jaguar Health Reduces Royalty Interest with Stock Exchange